Keros Therapeutics Appoints Anne Prener to its Board of Directors
Keros Therapeutics appointed Anne Prener, M.D., Ph.D., to its Board of Directors effective July 1, 2026, adding significant clinical development and executive leadership experience to the board. Dr. Prener previously served as CEO of Imbria Pharmaceuticals, Freeline Therapeutics, and Gyroscope Therapeutics, and held senior leadership roles at Novo Nordisk and Baxalta.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.